Pieter Proot

Publication Activity (10 Years)

Years Active: 2020-2020
Publications (10 Years): 2

Top Topics

Randomized Controlled Trial

Top Venues

Obesity (Silver Spring, Md.)

British journal of clinical pharmacology

Novartis Pharma AG

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Novartis Pharma AG Dec 01 2000

Switzerland

Clinical Development Director :: Clinical Development

Publications

Rudolf A de Boer, Julio Núñez, Plamen Kozlovski, Yi Wang, Pieter Proot, Deborah Keefe
Effects of the dual sodium-glucose linked transporter inhibitor, licogliflozin vs placebo or empagliflozin in patients with type 2 diabetes and heart failure. British journal of clinical pharmacology 86 (7) (2020)
Harold E Bays, Plamen Kozlovski, Qing Shao, Pieter Proot, Deborah Keefe
Licogliflozin, a Novel SGLT1 and 2 Inhibitor: Body Weight Effects in a Randomized Trial in Adults with Overweight or Obesity. Obesity (Silver Spring, Md.) 28 (5) (2020)